First slide

Due to increase in customer demand, Lonza announced to invest approximately $930 million to expand its mammalian drug substance manufacturing facilities in Visp (CH) and Portsmouth (US). The new facility will expand capacity with six 20,000L bioreactors to meet increasing market demand in biologics.

  • The new facility will have an area of approximately 27,500 m2.
  • The state-of-the-art, high throughput facility includes perfusion capabilities and is designed to support high titer processes and accommodate the next generation of mammalian biologics.
  • In April, Lonza announced to invest $215mn to construct a new manufacturing facility in Visp, Switzerland. The new 2000 m2 molecule manufacturing facility will include a customer dedicated manufacturing line for antibody-drug conjugate payload molecules.

The prominent deals and partnerships by Lonza are mentioned below:

April 2021: Lonza and Immunitas Therapeutics announced an agreement to advance the manufacturing process for the company’s lead drug candidate, IMT-009, using a customized, accelerated version of Lonza’s Ibex® Design program. Under the terms of the agreement, Lonza’s Ibex® Design end-to-end offering will cover the development stages of IMT-009 from Development Candidate through early clinical studies.

April 2021: Lonza, and Junshi Biosciences, an innovative Chinese pharmaceutical company, announced that the companies have expanded their collaboration for the development and manufacturing of biologics. Lonza will leverage its global network and local operation capabilities to help Junshi Biosciences accelerate the development of drugs in its pipeline and promote their adoption across global markets.

April 2021: Lonza announced the completion of the divestment of its Ploermel (FR) and Edinburgh (UK) sites to NextPharma. NextPharma is well placed to develop and grow both sites to their full potential.

March 2021: Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that it had expanded its previously-announced AdCOVID™ manufacturing collaboration with Lonza. Under the expanded agreement, Lonza will commission a dedicated manufacturing suite for clinical and commercial production of AdCOVID, Altimmune’s single-dose intranasal vaccine candidate for COVID-19, at its facility near Houston, Texas.

About Lonza:
Lonza headquartered in Basel, Switzerland, is a global chemicals and biotechnology company. The company is a leading global contract development and manufacturing organization (CDMO). The company focuses on treatments that prevent illness, support healthier lifestyles and create a healthy environment. The company has more than 15,500 employees and operates 120 sites and offices in around 35 different countries.

Related News